Clinical trials: Infections, Coronavirus
COVID-19
Evaluate the Efficacy and Safety of Oral Hydroxychloroquine, Indomethacin and Zithromax in Subjects With Mild Symptoms of COVID-19
Currently there are no US Food and Drug Administration (FDA)-approved drugs specifically for the treatment of patients with COVID-19.
- Trial name
- COVID-19 (NCT04344457)
- Testing
- Hydroxychloroquine, Indomethacin, Zithromax Oral Product
- Where
- 2 sites in United States
- Volunteers
- 80 people
- Sponsor
- Perseverance Research Center, LLC
Covid19
Protecting With ARNI Against Cardiac Consequences of Coronavirus Disease 2019
The purpose of this study is to determine the effect of sacubitril/valsartan versus placebo on markers of cardiac injury, structure, and function among patients who recovered from acute COVID-19 infection.
- Trial name
- PARACOR-19 (NCT04883528)
- Testing
- Sacubitril / Valsartan Oral Tablet [Entresto]
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- Duke University
Ebola Virus Disease, Marburg Virus Disease
Evaluation of Safety, Tolerability and Immune Responses of Ebola-S and Marburg Vaccines in Healthy Adults
Primary Objective: To evaluate the safety and tolerability of cAd3-EBO-S and cAd3 Marburg vaccines when administered Intramuscular (IM) at a dose of 1 x 10^11 particle units (PU) to healthy adults.
- Trial name
- NCT04723602
- Testing
- cAd3-Marburg, cAd3-EBO-S
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Albert B. Sabin Vaccine Institute
Coronavirus
Convalescent Plasma to Limit Coronavirus Associated Complications
Researchers are trying to assess the treatment potential and safety of anti-SARS-CoV-2 convalescent plasma in patients with acute respiratory symptoms with confirmed COVID-19.
- Trial name
- NCT04325672
- Testing
- Convalescent Plasma
- Sponsor
- Mayo Clinic
Covid19
Extracorporeal Blood Purification as a Treatment Modality for COVID-19
Several studies have suggested a potential clinical benefit of controlling hyper inflammation triggered by SARS-CoV-2/COVID-19. Blood purification, the removal of excessive proinflammatory mediators may control disease…
- Trial name
- NCT04478539
- Testing
- Extracorporeal blood purification using the oXiris® (AN69ST) hemofilter
- Where
- North Macedonia
- Volunteers
- 35 people
- Sponsor
- Zan Mitrev Clinic
COVID-19 Pneumonia
NO-mediated Vascular Function in Covid-19 Patient
The 2019 coronavirus-induced infection (COVID-19) has caused a pandemic that has spread worldwide. Up to date, many subjects affected by the virus report important sequelae on different organs increasing morbidity and…
- Trial name
- NCT04625036
- Testing
- Single passive leg movement
- Where
- Italy
- Volunteers
- 22 people
- Sponsor
- Istituti Clinici Scientifici Maugeri SpA
COVID-19
Immunogenicity And Safety of COVID-19 Vaccine , Inactivated Co -Administration With EV71 Vaccine (Vero Cell)
This study is a randomized and controlled Phase IV clinical trial of the COVID-19 vaccine (Vero cell), Inactivated manufactured by Sinovac Research \& Development Co., Ltd.
- Trial name
- NCT05107557
- Testing
- Experimental Group
- Where
- 2 sites in China
- Volunteers
- 520 people, healthy volunteers welcome
- Sponsor
- Sinovac Biotech Co., Ltd
COVID-19
Utility of Lactoferrin as a Preventive Agent for Healthcare Workers Exposed to COVID-19
COVID 19, which probably started from zoonotic transmission related to crowded markets in China was announced as a pandemic by the WHO on 11 March 2020.
- Trial name
- NCT04427865
- Testing
- prophylactic lactoferrin daily
- Volunteers
- 200 people
- Sponsor
- Cairo University
COVID-19
The Safer At School Early Alert HUB
Schools serve important community roles beyond academic education. In historically marginalized communities they are trusted providers for a range of support services for families in need.
- Trial name
- SASEA HUB (NCT05642000)
- Testing
- SASEA HUB
- Where
- United States
- Volunteers
- 1,029 people, healthy volunteers welcome
- Sponsor
- University of California, San Diego
SARS-CoV2 Infection
LIPId Profile Changes in Inflammatory Conditions Induced by SARS-CORoronavirus-2
In late 2019, a new coronavirus called severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was identified as the cause of COVID-19 (COronaVIrus Disease-2019) in Hubei Province, China.
- Trial name
- LIPICOR (NCT05113836)
- Testing
- Deep nasopharyngeal swab, Blood sample at D1, D3 and D7
- Where
- France
- Volunteers
- 89 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
COVID-19
Hydroxychloroquine for the Treatment of Mild COVID-19 Disease
The current outbreak of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome corona virus 2 (SARS-CoV-2) is a global health emergency with a case fatality rate so far approximately 4% and a growing…
- Trial name
- COMIHY (NCT04340544)
- Testing
- Hydroxychloroquine
- Where
- Germany
- Volunteers
- 17 people
- Sponsor
- University Hospital Tuebingen
Covid19, Children, Only
SeroCovid<19: Covid-19 Seroconversion in Tertiary Pediatric Patients
Children are relatively spared from the direct clinical impact of COVID-19. Pediatric patients with regular follow-up at tertiary pediatric centres and presenting one or more chronic conditions might be at increased risk for…
- Trial name
- NCT04615000
- Testing
- SARS-CoV-2 serological assessment (IgG)
- Where
- Belgium
- Volunteers
- 362 people
- Sponsor
- University Hospital, Ghent
SARS-CoV-2 Infection, Influenza A
Project STARFISH - PRJ0002679
This is a non-interventional study to perform the clinical performance evaluation of the Starfish Test using prospectively collected matched nasopharyngeal and nasal swab samples from the same donor.
- Conditions
- SARS-CoV-2 Infection, Influenza A, Influenza Type B, RSV Infection
- Trial name
- STARFISH (NCT05727202)
- Testing
- The Applied Biosystems™ TaqPath™ COVID-19, Flu A, Flu B, RSV Select Panel
- Where
- 17 sites in United States
- Volunteers
- 1,909 people
- Sponsor
- Thermo Fisher Scientific, Inc
Bioavailability
Relative Bioavailability Study of 4 Different Formulations of PF-07321332 Relative to the Commercial Tablet Formulation
The purpose of this study is to estimate the relative bioavailability of PF-07321332 in different formulations in healthy adult participants.
- Trial name
- NCT05263895
- Testing
- PF-07321332/ritonavir, PF-07321332
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Pfizer
Covid-19
The Study of Quadruple Therapy Zinc, Quercetin, Bromelain and Vitamin C on the Clinical Outcomes of Patients Infected With COVID-19
There are currently no antiviral drugs with proven efficacy nor are there vaccines for its prevention. Unfortunately, the scientific community has little knowledge of the molecular details of SARS-CoV-2 infection.
- Trial name
- NCT04468139
- Testing
- Quercetin, bromelain, Zinc
- Where
- Saudi Arabia
- Volunteers
- 60 people
- Sponsor
- Ministry of Health, Saudi Arabia
COVID19
Nitric Oxide Inhalation Therapy for COVID-19 Infections in the ED
The spread of novel Coronavirus (2019-nCoV) related infection (COVID-19) has led to many patient presentations in the emergency department for respiratory complaints, with many of these patients requiring ICU admission and…
- Trial name
- NO COV-ED (NCT04338828)
- Testing
- Nitric Oxide Gas, Inhaled Supplemental Oxygen
- Where
- United States
- Volunteers
- 47 people
- Sponsor
- Massachusetts General Hospital
Covid19, Sars-CoV-2 Infection
Performance Study of SONA Saliva C-19 Rapid Test
The Sona Saliva C-19 Rapid Test is a bioassay intended for rapid point-of-care detection of the SARS-CoV-2 virus. Performance of the Sona Saliva C-19 Rapid Test assay will be assessed by comparison to a RT-PCR reference method
- Conditions
- Covid19, Sars-CoV-2 Infection, Corona Virus Infection
- Trial name
- NCT04877002
- Testing
- Sona Saliva C-19 Rapid Test
- Where
- Canada
- Volunteers
- 20 people
- Sponsor
- Sona Nanotech Inc
Covid-19, Viral Infection
Dissemination of SARS-COV-2 (COVID-19) in the Environment of Infected Patients Admitted to Intensive Care Unit
The objective of this protocol is to estimate the proportion of patients hospitalized in intensive care unit for a SARS-Cov-2 viral lung infection and contaminating their environment at 1 meter.
- Trial name
- ENVIROREA (NCT04355481)
- Where
- 3 sites in France
- Volunteers
- 150 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Middle East Respiratory Syndrome Coronavirus (MERS-CoV)
Safety, Tolerability and Immunogenicity of INO-4700 for MERS-CoV in Healthy Volunteers
The purpose of this Phase 2a, randomized, blinded, placebo-controlled, multi-center study is to evaluate the safety, tolerability and immunogenicity of INO-4700 administered by intradermal (ID) injection followed by…
- Trial name
- NCT04588428
- Testing
- INO-4700, CELLECTRA™ 2000
- Where
- 6 sites in Jordan, Kenya and 1 more
- Volunteers
- 192 people, healthy volunteers welcome
- Sponsor
- Inovio Pharmaceuticals
Anxiety, Depression
Improving Mental Health Among the LGBTQ+ Community
The overall aim of this program of research is to improve the mental health of people who identify as LGBTQ+ by increasing their social support through a brief intervention.
- Trial name
- NCT05540067
- Testing
- Acceptance-Based Behavior Therapy (ABBT), Treatment-as-Usual (TAU)
- Where
- United States
- Volunteers
- 240 people
- Sponsor
- Brown University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.